Suzhou Yabao cooperates with Eli Lilly to develop glucokinase activator (GKA). The project has completed phase I clinical in the United States and completed the application of Chinese clinical approval on July 3, 2015. This is a class 1.1 innovative drug declared for clinical use by Suzhou Yabao.
Diabetes is a disease that is not satisfied in China and around the world. Unlike other diabetes drugs, the kinase activator has two potential effects: promoting insulin secretion and reducing glucose production in the liver. Therefore, glucokinase activators can have a strong inhibitory effect on hyperglycemia even in patients who are relatively ineffective with other oral drugs.
Suzhou Yabao is committed to continuously developing revolutionary drugs with international prospects by establishing cooperation with scientists and enterprises around the world, introducing innovative products and taking advantage of China's new drug development advantages.
Suzhou Yabao pharmaceutical R & D Co., Ltd. (hereinafter referred to as "Suzhou Yabao") officially settled in the biological nano Park of Suzhou Industrial Park in April 2014. It was founded and served as president by Dr. Wang Peng, a distinguished expert of the national "thousand talents plan". It is a group holding subsidiary of Yabao pharmaceutical, a well-known domestic pharmaceutical listed company. Suzhou Yabao is committed to the development and international cooperation of class 1.1 innovative drugs. It has established cooperative relations with Lilly pharmaceutical, University of South Australia, University of Western Ontario, science and Technology Department of National Medical College and other world-famous enterprises and colleges. The company has established a domestic innovative drug development team, and each field is presided over by leaders immersed in the development of innovative drugs at home and abroad for many years. Suzhou Yabao strives to create international innovative drugs in the field of major diseases and become a successful model of innovative drug research and development in China.
请将简历发送至：